Skip to main content
Scientist in lab coat and gloves examining a sample with a microscope.
Scientist in lab coat and gloves examining a sample with a microscope.

Translating new targets into precision oncology therapies

Built to unlock and target cancer's core vulnerabilities and dependencies. We are advancing precision medicines and rational combinations designed to address the underlying drivers of molecularly defined cancers.

Our pipeline at-a-glance

A rationally designed pipeline of targeted small molecule therapies and antibody-drug conjugates (ADCs), focused on enabling combination strategies and advancing potential first- or best-in-class medicines for people with hard-to-treat cancers.

Comparison chart of immunotherapies, pathways, benefits, and response rates for melanoma treatments.

Asset
Study Overview
Phase 1
Phase 2
Phase 3Potential Registrational
Collaboration Partner
Darovasertib Target: PKC
Investigational darovasertib in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma (mUM)
PHASE 3: Registrational Phase
Darovasertib Target: PKC
Phase 1/2 study of darovasertib in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions
PHASE 2
Darovasertib Target: PKC
Randomized, phase 3, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic UM
PHASE 3: Registrational Phase
Darovasertib Target: PKC
Phase 2 multi-center open-label darovasertib study in patients with primary UM requiring either enucleation or plaque brachytherapy
PHASE 2
Darovasertib* Target: PKC
Adjuvant primary UM + crizotinib1 combination
PHASE 2

*Targeting Phase 3 initiation in H1 '26

Asset
Study Overview
Phase 1
Phase 2
Phase 3Potential Registrational
Collaboration Partner
IDE849 Target: DLL3
Phase 1/2, multicenter study evaluating the safety, efficacy, and pharmacokinetics of IDE849 in patients with DLL3-expressing tumors including small cell lung cancer. Part 1A dose escalation will evaluate IDE849 monotherapy
PHASE 2
IDE849 Target: DLL3
Phase 1/2, multicenter study evaluating the safety, efficacy, and pharmacokinetics of IDE849 in patients with DLL3-expressing tumors including small cell lung cancer. Part 1B dose escalation will evaluate IDE849 in combination with durvalumab or IDE161
PHASE 1
IDE034 Target: B7H3/PTK7
Open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of IDE034 in adult Participants with locally advanced/metastatic solid tumors
PHASE 1
IDE161 Target: PARG
A study of PARG Inhibitor IDE161 in participants with advanced solid tumors
PHASE 1

Asset
Study Overview
Phase 1
Phase 2
Phase 3Potential Registrational
Collaboration Partner
IDE397 Target: MAT2A 
Open label, phase 1, treatment study to evaluate the safety, pharmacokinetics and pharmacodynamics of IDE397 (MAT2A inhibitor) in adult participants with advanced solid tumors
PHASE 2
IDE892* Target: PRMT5
Multicenter study evaluating the safety, efficacy, and pharmacokinetics of IDE892 as monotherapy and combination therapy in participants with MTAP-deleted advanced solid tumors
PHASE 1

*Pending monotherapy dose escalation from cohort 2

Asset
Study Overview
Phase 1
Phase 2
Phase 3Potential Registrational
Collaboration Partner
IDE574 Target: KAT6/7
Study to investigate the safety, pharmacokinetics, and preliminary efficacy of IDE574 therapy in adult participants with advanced solid tumors 
PHASE 1

Discover IDEAYA

Scientist wearing gloves and glasses looking through a microscope.

Learn more about us

Learn more
Scientists in lab coats talking, overlaid by a colorful lightbulb graphic.

Explore IDEAYA Ideas

Learn more
Modern office building with glass windows near a waterfront, palm trees, and parked cars.

Read our latest news

Learn more

PKC = protein kinase C, 1L = first line, ADC = antibody drug conjugate HLA = human leukocyte antigen, SCLC = small cell lung cancer, NEC = neuroendocrine carcinoma, NSCLC = non-small cell lung cancer, CRC = colorectal cancer, HNSCC = head and neck squamous cell carcinoma